GlycoMimetics, Inc.

Crescent Biopharma may be behind in the race to introduce a PD-1xVEGF bispecific antibody, but the firm has a clearer path now that it is going public through a reverse merger with GlycoMimetics and

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp

GlycoMimetics, Inc. is hoping that mining the data from its failed Phase III pivotal trial of uproleselan in acute myeloid leukemia (AML) can potentially yield some evidence of benefit in subgroup po

The Biotechnology Innovation Organization’s new president and CEO John Crowley brings to the role more than two decades of experience in the biotech drug industry and a strong history of rare disease